Pro Health Tips
Wednesday 26 February 2020
U.S. FDA Accepts Application for Niraparib For Ovarian Cancer
Submission of supplemental New Drug Application (sNDA) to the U.S F.D.A was based on data from the Phase III PRIMA study on niraparib as maintenance treatment for ovarian cancer patients.
from Medindia Health News https://ift.tt/32x7fW7
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
Submission of supplemental New Drug Application (sNDA) to the U.S F.D.A was based on data from the Phase III PRIMA study on niraparib as maintenance treatment for ovarian cancer patients.
No comments:
Post a Comment